Human interferon-y (IFN-7)-inducible protein 10 (IP-101, a C-X-C chemokine, is secreted by IFN-y-stimulated keratinocytes and is chemotactic for CD4+ lymphocytes. We therefore investigated its role in the epidermotropism of cutaneous T-cell lymphoma (CTCL) that is known to express IFN-y mRNA in the epidermis and is characterized by an indolent course with multiple relapses that remain confined to the skin for many years. By injecting purified recombinant (r) IP-10 we generated a polyclonal rabbit antiserum that specifically recognized and neutralized rlP-10. With immunoperoxidase staining, IP-10 expression was limited to the basal epidermal keratinocytes of normal skin. In biopsies of CTCL lesions the expression of IP-10 was markedly increased and it extended to the suprabasal keratinocytes in 17 of 18 patients, but it was detectable only faintly in the dermal or C UTANEOUS T-CELL lymphoma (CTCL) is an indolent lymphoproliferative disorder, usually preceded by a prolonged premalignant dermatitis. CTCL is almost always a disease of mature postthymic CD4+ lymphocytes that have a cerebriform nucleus and rearranged T-cell antigen receptors. Pathologically, the diagnosis of CTCL is based on the presence of both architectural (band-like lymphoid infiltrate in the upper dermis and sterile Pautrier's microabscesses in the epidermis) as well as cytological atypia (malignant infiltrating lymphocytes with cerebriform nuclei).' Mycosis fungoides designates CTCL involving the skin with patches, placques, and tumors and Pautrier's microabcsesses, whereas Sezary syndrome designates CTCL with malignant cells in the peripheral blood in association with generalized erythroderma and variable degrees of cutaneous infiltration by malignant lymphocytes. However, conservative measures, such as topical alkylating agents, ultraviolet light, low-dose methotrexate, and spot radiotherapy, or a combination of intensive chemotherapy and total skin electron-beam radiotherapy can induce remissions that are not durable in most patients. ' The disease usually remains limited to the skin for many years and extends to lymph nodes and viscera or transforms to large-cell lymphoma only late in its natural hi~tory. ~ We were intrigued by the report that the epidermis of human CTCL lesions express mRNA for interferon-y (IFW 7): which, in turn, can induce keratinocytes to secrete IFNy-inducible protein-l0 (IP-10).5 Because IP-l0 is chemotactic for human CD4+ lymphocytes,6 we investigated its role in the pathogenesis of CTCL.
Human IP-IO was cloned as an IFN-y-inducible cDNA from U-937 cells536 but was also induced in vitro in many cell lines by lipopolysaccharide, tumor necrosis factor (TNFa), IFN-y, interleukin-la (IL-la), and IL-6.7-9 In vivo administration of TNF-a or IFN-y induced expression of IP-10 in skin or IP-10 belongs to the chemokine family that includes small secreted basic proteins of approximately 7 to 10 k D . The family was so named because of the activating and chemotactic properties of its members towards epidermal lymphoid infiltrates in 2 of these 18 patients. In 1 patient who had matching biopsies performed before and after treatment, IP-10 was overexpressed before treatment, but was normally expressed in the posttreatment biopsy that showed resolution of the CTCL. Increased IP-10 expression was not detected in any of 4 patients with B t e l l lymphoma involving the dermis. On the basis of these findings and a review of the literature, we propose that secretion of IFN-y by the lymphoid infiltrate in CTCL induces the epidermal keratinocytes t o secrete IP-10 that, in turn, is chemotactic for CTCL, accounting for its epidermotropism. This model may be used as a basis for future investigations of the pathogenesis of CTCL. neutrophils, monocytes, and lymphocytes. The chemokines are divided into two subfamilies by the arrangement of the first two of four conserved cysteines that are adjacent in the C-C or P subfamily but are separated by one amino acid residue in the C-X-C or a subfamily. The latter, in addition to IP-10, includes P-thromboglobulin (P-TG), GRO-a, IL-8, neutrophil-activating peptide 2 (NAP-2), macrophage inflammatory protein (MIP)-k, and MIP-2P, whose genes are clustered on human chromosome 4q12-21.'3*'4 The chemokines exert their actions by binding to specific serpentine cell-surface receptors coupled to G-proteins, but the steps following receptor binding have not yet been completely elucidated."
Initial studies suggested that secreted IP-10 migrated with an apparent size of 6 to 7 kD on sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and was not immunoprecipitated with an antiserum raised against a 652 SARRIS ET AL synthetic peptide corresponding to the 22 carboxy-terminal residues of its predicted sequence. This finding led to a hypothesis that IP-10 was secreted after removal of the signal sequence and also after additional proteolytic removal of approximately 22 residues from the carboxy-terminal end.' By expressing defined fragments of IP-10 in Escherichia coli we showed that inaccurate estimates of molecular weight accounted for the previously reported size of IP-10 that migrates on SDS-PAGE with an approximate size of 10 k D . Furthermore, we showed with immunoprecipitation and Westem blotting that the antiserum raised against the 22 carboxy-terminal residues recognized both natural and recombinant (r) IP-10. We suggested that the previous results could be explained by inadequate exposure of the cognate epitopes because of insufficient IP-10 denaturation. We concluded that naturally occurring IP-10 was secreted after removal of the signal sequence without any detectable posttranslational processing of the carboxy-terminal end and contained amino acid residues 22 to 98 of the predicted sequence. We designated the natural form of IP-l0 as f(22-98), and by expression and purification in E coli, we showed that it inhibited early subsets of human hematopoietic progenitors.I6 Human IP-l0 corresponding to f(22-98) was chemotactic for human monocytes and CD4+ lymphocytes" but was inactive for neutrophil^.^^^'^ The chemotactic activity of IP-10 may account its in vivo antitumor activity." We now report our immunocytochemical investigation of IP-10 expression in CTCL lesions and propose a model in which a cytokine loop consisting of IFN-y, secreted by lymphocytes, and IP-10, secreted by epidermal keratinocytes, may explain the epidermotropism of CTCL.
MATERIALS AND METHODS
Human rIFN-y was a gift from Dr G. Garotta (Hoffman-LaRoche, Basel, Switzerland). Human recombinant granulocyte-macrophage colony stimulating factor (&M-CSF), rIL-3, and steel factor (rSLF) were gifts of the Immunex Corp (Seattle, WA). Human rMIP-la, rMIP-lP, rMCP-I, rMCP-2, rMCP-3, rRANTES, rIL-8, rGRO-a, and rC-l0 were generous gifts of Dr Dennis Taub (National Cancer Institute, Frederick, MD). Human rIP-10 was purified from baculovirus or E coli as previously described.I6
AS522 is a polyclonal antiserum generated by immunizing rabbits with f(22-98) purified from E coli.'6 Recombinant protein (500 pg) was emulsified with complete Freund's adjuvant and injected intradermally in rabbits with booster injections of 250 pg in incomplete Freund's adjuvant every 2 weeks. Antibodies were detected by enzyme-linked immunosorbent assay (ELISA) using purified f(22-98) and a method described for MIP-la?' Titers were defined as the serum dilution giving half-maximal color development in ELISA. Biotinylated goat antirabbit IgG, streptavidin peroxidase, and 3,3'-diaminobenzidine were from Sigma Chemical CO (St Louis, MO). Sera were stored frozen at -20°C in small aliquots. For use they were thawed, diluted in phosphate-buffered saline (PBS) containing 0.02% sodium azide, stored at 4"C, and used as described.
The ability of AS522 to recognize denatured IP-10 was determined by Western blotting," and its ability to recognize native IP-10 was determined by ELISA" and by neutralization of the inhibitory activity of rIP-10 against normal hematopoietic progenitors.'6 To this effect, 105 human low-density bone marrow cells from healthy volunteers isolated by density separation using Ficoll-Hypaque (Pharmacia, Piscataway, NJ) were plated in methylcellulose in McCoy's medium in the presence of fetal calf serum, rGM-CSF (100 U/ mL), and rSLF (50 ng/mL) with or without rIP-IO. Granulocytemacrophage colonies (>40 cells; colony-forming units granulocytemacrophage [CFU-GM]) were scored after incubation at 3 7 T , 5% CO2, and 5% O2 for 14 days. Neutralization of IP-l0 was performed by incubation of the medium containing rIP-IO with excess whole AS522 at room temperature for 1 hour. The mixture was then added to lo5 low-density human bone marrow cells that were immediately plated. For control, an equal volume of similarly incubated McCoy's medium was added to cells.
Patients referred to The University of Texas M.D. Anderson Cancer Center were included in this study if their frozen punch biopsy specimens were available and if the diagnosis of CTCL was confirmed by a combination of all available data including the clinical presentation, microscopic examination of paraffin-embedded tissue, immunophenotypic analysis, and detection of clonal T-cell antigen receptor gene rearrangements by Southern blotting. We obtained appropriate signed informed consent for all biopsies as required by institutional guidelines. Stage was determined as described." Immunoperoxidase staining was performed on frozen punch biopsy sections from involved and uninvolved skin of patients with CTCL and on normal skin obtained from patients without CTCL during other operations. Skin biopsy samples were embedded in TissueTek OCT (Miles, Naperville, IN) and snap frozen in liquid nitrogen. Four-micrometer sections were cut with a cryostat, placed on poly-L-lysine-coated slides, air-dried, and fixed in 100% acetone for IO minutes at room temperature. After destruction of endogenous peroxidase by incubation in 0.3% hydrogen peroxide in methanol, the sections were incubated for 30 minutes at room temperature with AS522 diluted 200-to 400-fold followed by biotinylated goat antirabbit IgG and then by streptavidin-peroxidase. Color was developed with 3,3'-diaminobenzidine, and the sections were then counter stained with Mayer's hematoxylin and photographed through a Nikon light microscope (Nikon, Inc, Melville, NY). Negative control reactions for the specificity of staining included incubation with nonimmune rabbit serum or omission of the immune serum. Positive control for the presence of protein in the sections was staining with antibodies for type I transglutaminase-l.23
RESULTS
We generated a polyclonal rabbit serum (AS522) against IP-10 by expressing and purifying from E coli rIP-10 that was indistinguishable from natural IP-10. Western blotting showed that this antiserum reacted only with IP-10 from supernatants of normal epidermal keratinocytes (Fig l) , thus excluding the possibility that the subsequent immunoperoxidase staining reflects staining with antibodies against minor human proteins contaminating the rIP-IO preparation. Specificity of AS522 for IP-10 was also confirmed with ELISA, for which its titer was 3,000 (results not shown) and for which, at a dilution of 1/1,000, AS522 recognized native rIP-10 but not rMIP-la, rMIP-18, rMCP-1, rMCP-2, rMCP-3, rRANTES, rIL-8, rGRO-a, or rC-l0 (Fig 2) . The ability of AS522 to specifically recognize native rIP-l0 was also shown by neutralization of the suppressive activity of rIP-10 in the hematopoietic progenitor colony assay (Fig 3) . Addition of rIP-10 to low-density marrow cells did not affect the number of CFU-GM generated by plating with &M-CSF. The addition of rSLF to rGM-CSF doubled the number of colonies, and under these conditions rIP-10 caused a dosedependent reduction in CFU-GM. Maximum inhibition reduced the CFU-GM number to that obtained by plating with &M-CSF alone. Preincubation of control medium with excess AS522 had no effect on colony formation, but preincubation of medium containing rIP-l0 with excess AS522 abolished the inhibitory effect of rIP-l0 (Fig 3) . Even under conditions of antibody excess, AS522 did not recognize rIL-8, rPF4, or rMIP-la because it did not affect their inhibitory activity in the hematopoietic progenitor assay.I6
The subjects of this study were 18 previously untreated patients with CTCL whose clinical characteristics are shown in Table 1 showed that IP-l0 expression was limited to basal keratinocytes (Fig 4A) , as previously reported.24 There was no staining in the absence of primary serum or with nonimmune rabbit serum (data not shown). Staining of biopsy samples from the CTCL lesions showed increased expression of IP- 10 in basal and suprabasal keratinocytes (Fig 4B through E) in 17 of 18 patients (Table 1) . Only 1 patient who had epidermotropism had no detectable epidermal IP-10 expression (Table 1 , patient no. 10). In 1 patient with sufficiently large biopsy, the expression of IP-10 was increased in the epidermis immediately overlying the malignant lymphoid infiltrate (Fig 4E, small arrowheads) but was normal in intensity and distribution in more distant epidermis. This finding suggested that a diffusable factor secreted by the malignant lymphocytes (Fig 4E, large arrowheads) induced IP-10 secretion by keratinocytes. All 6 patients with stage IV CTCL had circulating Sezary cells and simultaneous epidermotropism with overexpression of IP-10 in epidermal keratinocytes overlying the lymphomatous infiltrates. Higher magnification showed that IP-10 was faintly expressed in the lymphoid infiltrates of only 2 patients, 1 with mycosis fungoides and 1 with Sezary syndrome (Fig 4E and Table 1 ) but was undetectable in those of the remaining 16 (Fig 4C  and D) . In the 1 patient who had biopsies of the same lesion at presentation and after therapy-induced remission, the IP-10 immunoreactivity was increased before but was normal after treatment (patient no. 7, Table 1 ). Increased IP-10 expression was not detected in 4 patients with B-cell lymphoma that involved the skin but did not exhibit any epidermotropism (Fig 4F) .
DISCUSSION
We used purified bacterial rIP-10 to generate a polyclonal rabbit antiserum that recognized denatured and native rIP-10 but not other chemokines, especially RANTES, MCP-1, MIP-la, and MIP-l@, that are chemotactic for T lymphocytes.*s Immunoperoxidase staining showed qualitative and quantitative differences in IP-10 expression between CTCL and normal skin. The IP-10 expression was higher in CTCL where it extended to the suprabasal keratinocytes overlying the lymphomatous infiltrates. Even though IP-10 can be secreted in vitro from monocytes and activated lymphocytes,h it was detected in the malignant lymphocytes of only 2 of 18 patients with CTCL. Remission-inducing therapy eliminated most malignant lymphocytes and normalized the IP-10 expression in areas of prior cutaneous lesions. The overexpression of IP-10 appeared to be specific for CTCL, because it was not seen in the biopsies of 4 patients with B-cell lymphoma involving the dermis.
Based on previously formulated models for the trafficking of lymphocyte^,^^^*^ we propose a model in which epidermal keratinocytes, benign or malignant lymphocytes, and cytokine loops involving IFN-y and IP-10 play pivotal roles in the pathogenesis of CTCL (Fig 5) . This model includes three sequential and partly overlapping steps. First, skin-homing T lymphocytes return to skin by binding of the cutaneous lymphocyte-associated antigen (CLA)** to E -~e l e c t i n~~ that is expressed in skin in delayed hypersensitivity3' and chronic inflammation*' that often precede CTCL. The second step, ie, lymphocyte activation, occurs when keratinocyte-secreted IP-10 binds to cell-surface receptors and activates lymphocytes, causing their migration to the epidermis. Lymphocyte activation is associated with conformational changes on their cell-surface integrins that mediate the third step, ie, their strong binding to intercellular adhesion molecules (ICAMs) on keratinocytes, and cause the subsequent lymphocyte retention in the epidermis. These three steps would result in the formation of the sterile Pautrier's microabcesses characteristic of CTCL. The focal overexpression of IP-l0 over CTCL lesions strongly suggests that a diffusible inducer of IP-10 is secreted by either the malignant or the reactive lymphocytes of the lymphoid infiltrate. We suggest that this factor is IFN-y, which induces keratinocytes to secrete IP-10 and also express ICAMs, thus enabling them to attract and to retain CD4+ lymphocytes in the epidermis. We cannot specify whether IFN-y is secreted by the malignant or the reactive lymphocytes of the CTCL lesions. Because IFNy mRNA has been localized to the epidermis of mycosis f~n g o i d e s~~~'~' * where most clonal T lymphocytes are localized:' it is possible that IFN-./ is secreted by the malignant epidermotropic lymphocytes. The basis for the expression of IFN-y is undefined but might be the t d r e x region of HTLV-I that is frequently detected by polymerase chain reaction amplification in blood mononuclear cells34 and cutaneous lesions of patients with CTCL.'5 Transfection experiments have shown that the taxhex region is necessary and sufficient for immortalization of primary human CD4' lymphocytes" and that it trans-activates the IFN-y promotor in human lymphoid lines.37 We have immunocytochemical evidence confirming the expression of IFN-y in the lymphoid infiltrates of CTCL (Sarris, Ulmer, and Duvic, unpublished observations), but additional work is needed to fully define the identity and the source of the IP-10 inducer.
There is published evidence supporting this model. Epi- keratinocytes to IFN-y would also induce secretion of IP-10, and the resulting activation of the malignant lymphocytes would enable them to bind to ICAM-1 .3R
Our 6 patients with Sezary syndrome had circulating malignant cells and simultaneously had epidermotropism and overexpression of IP-IO in the lesional epidermis. This finding can be explained by the coexistence of two malignant cell populations in our patients with Sezary syndrome, ie, the epidermotropic cells the form the skin lesions and the circulating cells. The existence of two populations was previously suggested: but it remains unclear whether they represent two separate compartments or whether malignant cells can move from the circulating to the epidermotropic compartment. Our model suggests testable hypotheses for the generation of the nonepidermotropic population. These hypotheses include chemokine receptor mutation or deletion, as suggested by the profound leukocytosis caused by knockout of the murine IL-8 receptor homologue:' Other possibilities include deficient postreceptor signaling, deficient expression of integrins, and an altered cytokine secretion pattern that renders the circulating cells unresponsive to chemotactic signals originating from the epidermis. In fact the circulating CD4' lymphocytes purified from the peripheral blood of patients with Sezary syndrome had mRNAs for IL-4, IL-5, and IL-l0 but not for IFN-y,4."'"' and this deficiency in IFNy secretion could not be overcome by phytohemagglutinin or phorbol esters?* This model explains both the epidermotropism of malignant lymphocytes and their preferential localization in the epidermis3? Combined with the demonstration that most epidermal but few dermal lymphocytes are proliferating:3 it also suggests that the epidermotropism is essential for the growth of CTCL and may explain the repeated cutaneous relapses and lack of initial clinical visceral dissemination in patients with Sezary syndrome. It also provides a framework to explain the therapeutic effects of cyclosporin-A and interferons in CTCL. As reported, even when the lymphoma responds, it always relapses shortly after the discontinuation of cyclosporin-A, regrows rapidly to the pretreatment volume, and then slows down to its previous pace." Because cyclosporin-A is cytostatic, it may act by inhibiting IFN-y production by T cells4' and eliminating the inducer of IP-10. It is likely that, after the discontinuation of cyclosporin-A treatment, the synthesis of IFN-y resumes, the cytokine loops are reestablished, and the malignant lymphocytes rapidly return to the epidermis explaining the appearance of very rapid tumor regrowth that paradoxically slows down once it reaches its pre-cyclosporin-A bulk. IFN-(Y or I F Ny, both active against CTCL:' can, at low concentrations, induce but, at higher concentrations, suppress the induction of IP-IO mRNA in U-937 cells.' This dose-dependent effect of interferons provides a way to override the inductive effect of IFN-y on the synthesis of IP-IO by keratinocytes. Abolition of the epidermotropic IP-IO signal by either interferons or cyclosporin-A might lead to redistribution of CTCL to other visceral sites in the body, away from the epidermis where they divide,"3 and thus explain the observed therapeutic effects. The role played by the infiltrating reactive lymphocytes and by IP-IO in the host response to CTCL is undefined. Because only small amounts of IP-IO are rarely detectable in the lymphocytes of CTCL lesions, it probably does not mediate an antitumor response against CTCL as it did in immunocompetent mice challenged with syngeneic tumors that secreted high amounts of IP-10.2"
This model, developed in response to data presented here and reported in the literature, emphasizes that active participation of both keratinocytes and benign or malignant lymphocytes is important for the pathogenesis of CTCL. Thus, it provides a framework for the systematic investigation of the roles played by IP-IO (and possibly other chemokines), selectins, integrins, and adhesion molecules in the biology of CTCL. We hope that a more detailed understanding of the pathogenesis, growth control mechanisms, and clinical evolution of CTCL will help in the identification of new therapeutic agents with novel mechanisms of action. Possible candidates are peptides or antibodies capable of blocking chemokine-receptor binding or molecules that inhibit signal transduction after chemokine-receptor binding. Novel therapeutic agents are clearly needed because, at present, there is no curative treatment for most patients with CTCL. 
